XML 89 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Accounts receivable $ 494 $ 1,034  
Takeda Agreement | Sales-Based Royalties      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Royalties received 0 0  
Takeda Pharmaceutical Company Limited | Takeda Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Upfront payment received     $ 10,000
Accounts receivable 500 1,000  
Deferred revenue   13,600  
Maximum milestone payment associated with development and commercialization upon milestone to be achieved 180,000    
Milestone payments received under agreement 4,000    
Remaining revenue performance obligation 0    
Takeda Pharmaceutical Company Limited | Takeda Agreement | Collaboration Revenue      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Revenue recognized 18,500 7,400  
Open Biome | Asset Purchase And License Agreement | Sales-Based Royalties      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Royalty revenue 0 300  
Open Biome | LMIC Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Revenue recognized 0 $ 0  
Open Biome | LMIC Agreement | Sales-Based Royalties      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Royalty revenue $ 0